310.ai Company Profile

Background

310.ai, founded in 2022 and headquartered in San Francisco, California, is a biotechnology company at the forefront of integrating generative artificial intelligence (AI) with molecular programming. The company's mission is to develop an AI operating system for life sciences, enabling programmable biology through advanced AI models.

Key Strategic Focus

310.ai's strategic focus centers on creating generative AI solutions that facilitate the design of novel biomolecules. By leveraging cutting-edge AI technologies, the company aims to revolutionize protein design and development, making biology more accessible and impactful for real-world applications. Their primary markets include pharmaceuticals, agriculture, and environmental technology.

Financials and Funding

Since its inception, 310.ai has secured funding to support its innovative endeavors. In January 2023, the company completed a seed funding round led by Cota Capital, with participation from Ascend Vietnam Ventures.

Pipeline Development

310.ai has developed several key products and services:

Molecule Programming Foundational AI Model (MPM4): This model enables text-to-protein generation, allowing for the creation of new proteins based on textual descriptions.

310 Copilot: A web-based platform designed for biomolecule design, integrating AI models for database searching, visualization, and pipeline orchestration.

MP Repo: A repository containing over 1,053 AI-generated protein sequences, evaluated for structural and functional properties.

Technological Platform and Innovation

310.ai distinguishes itself through its proprietary technological platforms and innovative methodologies:

Generative AI Models: The company employs advanced AI models, including transformers, graph neural networks, and large language models (LLMs), to facilitate de novo protein design.

Computational Approaches: By integrating machine learning techniques with deep biological insights, 310.ai enables the design and optimization of proteins from scratch, a process known as de novo protein design.

Leadership Team

Kooshiar Azimian, Ph.D. – Founder & Chief Executive Officer: A serial entrepreneur and former Staff AI Engineer at Facebook, Kooshiar has a background in computer engineering and has founded multiple ventures, including Concertboom and Kookoo.ai.

Kathy Y. Wei, Ph.D. – Co-Founder & Chief Scientific Officer: With a Ph.D. from Stanford and postdoctoral training in computational protein design, Kathy has experience at Amgen, where she applied structure prediction and other techniques to support various therapeutic areas.

Leadership Changes

As of the latest available information, there have been no significant changes or appointments within 310.ai's leadership team.

Competitor Profile

Market Insights and Dynamics

The integration of AI in biotechnology is a rapidly growing field, with increasing investments and advancements in AI-driven drug discovery and molecular design. The market is characterized by a competitive landscape where innovation and technological capabilities are key differentiators.

Competitor Analysis

While specific direct competitors to 310.ai are not detailed in the available information, companies operating at the intersection of AI and biotechnology, such as those focusing on AI-driven drug discovery and protein design, represent the competitive landscape. These companies leverage AI technologies to accelerate research and development processes in life sciences.

Strategic Collaborations and Partnerships

310.ai has established relationships with investors such as Cota Capital and Ascend Vietnam Ventures, which provide not only financial support but also strategic guidance to strengthen the company's market position and innovation capacity.

Operational Insights

310.ai's strategic considerations include:

Technological Differentiation: By developing proprietary AI models for molecular programming, the company offers unique solutions in the biotechnology sector.

Market Positioning: Focusing on generative AI for biomolecule design positions 310.ai as a pioneer in programmable biology, catering to the needs of pharmaceuticals, agriculture, and environmental technology sectors.

Strategic Opportunities and Future Directions

Looking ahead, 310.ai aims to:

Expand Product Offerings: Continue developing and refining AI models and platforms to address a broader range of applications in life sciences.

Strengthen Industry Collaborations: Forge partnerships with research institutions and biotech firms to enhance the adoption and impact of their technologies.

Advance Technological Capabilities: Invest in research and development to stay at the forefront of AI and biotechnology integration, ensuring the delivery of cutting-edge solutions.